A biotechnology company, developing technologies and products to treat cancers and infectious diseases, based on immunological approaches.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Antigenics was a ten-bagger for anyone who bought it at recent lows of 0.3 and sold at an intra-day high over 3 this week. Hopefully if you were in a transaction this week you were a seller and not a buyer. Oncophage failed phase III trials years ago and the company has been stringing investors along with post hoc subset analyses and publicity stunts like getting approval in Russia, which has generated no meaningful revenue. God only knows how much truth is was in their recent survival advantage claims at ASCO. They've long ago lost any credibility with anyone who has followed biotech for more than a couple of years. I successfully red thumbed them after their Russian "approval" and I'm going to hit hard again now. This isn't Dendreon II, sorry.